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Since 2008, annual surveys of influenza vaccination 
policies, practices and coverage have been under-
taken in 29 European Union (EU)/ European Economic 
Area (EEA) countries. After 2009, this monitored 
the impact of European Council recommendation to 
increase vaccination coverage to 75% among risk 
groups. This paper summarises the results of three 
seasonal influenza seasons: 2008/09, 2009/10 and 
2010/11. In 2008/09, 27/29 countries completed the 
survey; in 2009/10 and 2010/11, 28/29 completed it. 
All or almost all countries recommended vaccination of 
older people (defined as those aged ≥50, ≥55, ≥59, ≥60 
or ≥65 years), and people aged ≥6 months with clini-
cal risk and healthcare workers. A total of 23 countries 
provided vaccination coverage data for older people, 
but only 7 and 10 had data for the clinical risk groups 
and healthcare workers, respectively. The number of 
countries recommending vaccination for some or all 
pregnant women increased from 10 in 2008/09 to 22 
in 2010/11. Only three countries could report coverage 
among pregnant women. Seasonal influenza vaccina-
tion coverage during and after the pandemic season in 
older people and clinical groups remained unchanged 
in countries with higher coverage. However, small 
decreases were seen in most countries during this 
period.  The results of the surveys indicate that most 
EU/EEA countries recommend influenza vaccination for 
the main target groups; however, only a few countries 
have achieved the target of 75% coverage among risk 
groups. Coverage among healthcare workers remained 
low.
Introduction
Influenza is a contagious viral respiratory infection, 
which typically occurs as epidemics during the win-
ter months in temperate zones. Although the illness 
caused by influenza is usually self-limiting, even in 
those outside recognised risk groups, it can cause 
considerable impact on an individual’s daily life. At 
a population level, large numbers of cases with mild 
to moderate severity of illness increase demands on 
health services and decrease productivity in the work-
force, with associated economic cost and social disrup-
tion [1-3]. The number of people affected varies from 
year to year among countries, making it hard to predict 
the annual number of deaths or economic impact. 
Annual influenza epidemics are associated with high 
morbidity and mortality. The European Centre for 
Disease Prevention and Control (ECDC) estimates that 
on average nearly 40,000 people die prematurely 
each year from influenza in countries of the European 
Union (EU)/European Economic Area (EEA) covered by 
Vaccine European New Integrated Collaboration Efforts 
(VENICE). VENICE covers all EU/EEA countries except 
Lichtenstein [4]. Death has been reported in 0.5–1 
per 1,000 cases of influenza, with the highest hospi-
talisation rates occurring among children less than two 
years of age and individuals ≥65 years in United States 
[5]. The most effective single public health intervention 
to mitigate and prevent seasonal influenza is vaccina-
tion [6]. Unlike the situation for most childhood vac-
cines, the European policy for influenza is protection of 
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those at higher risk either directly by vaccinating them 
or indirectly by vaccinating those who are likely to 
infect them (healthcare workers (HCWs) and pregnant 
women). Vaccination of pregnant women protects the 
women during and immediately after pregnancy and 
also decreases the risk to their infant [7]. 
The primary indicators of success in implementation of 
vaccination programmes are the group coverages, i.e. 
the proportion of specific target populations who have 
been vaccinated. In December 2009, the European 
Council unanimously recommended that EU countries 
adopt and implement national action plans to achieve 
75% influenza vaccination coverage in all at-risk groups 
by the influenza season of 2014/15 [8]. The selection of 
risk groups followed guidance from ECDC and recom-
mendations of the World Health Organization (WHO): 
‘older’ individuals (often defined as aged ≥65 years) 
and people of all ages above six months with under-
lying medical conditions [9-11], referred to in this arti-
cle as clinical risk groups. This EU recommendation 
encouraged countries to adopt and implement national, 
regional or local action plans or policies to improve 
seasonal influenza vaccination including among HCWs 
and to measure coverage in all risk groups. Countries 
were also encouraged to report on a voluntary basis 
to the European Commission on the implementation of 
the recommendation. ECDC-supported VENICE surveys 
have been to be the most effective way of doing this 
without placing additional reporting burdens on coun-
tries [12,13].
The overall aim of this paper is to document progress 
towards achieving the 75% coverage target in risk 
groups in the EU/EEA Member States since the 2009 
recommendation. More specific objectives are to pro-
vide an overview of data collected for pre-pandemic 
(2008/09), pandemic (2009/10) and post-pandemic 
(2010/11) influenza seasons in order to monitor the pro-
gress of specific items in the recommendation and to 
identify changes in country-specific vaccination recom-
mendations for the targeted age and risk groups during 
this period and also to report on vaccination coverage 
in the first season after the 2009/10 pandemic across 
EU/EEA countries.
Methods
The methodology of the VENICE project influenza 
surveys has been previously described [14-16]. In 
November 2011, VENICE conducted the fourth seasonal 
influenza vaccination survey and collected data for the 
2010/11 influenza season. This survey was a collabo-
rative study between EU/EEA countries, ECDC and the 
VENICE project group.
A standard questionnaire (similar to those used in pre-
vious years) was amended to reflect additional infor-
mation needs for the 2010/11 season. This can be seen 
in the full survey report [12,17]. Following a pilot phase, 
the questionnaire was placed on a restricted-access 
web platform. The questionnaire contained prefilled 
data from the previous survey relating to the 2009/10 
season. Experts (gatekeepers) of all 27 EU Member 
countries plus Norway and Iceland identified in each 
country at the beginning of the VENICE project in 2006 
were asked to update information on vaccination poli-
cies and action plans and were requested to provide 
the available vaccination coverage rates for the 2010/11 
influenza season.
We sought accurate and validated information on pop-
ulation groups that were targeted for influenza vacci-
nation (age, occupation, clinical risk or other groups, 
e.g. contacts of infants less than six months of age or 
immunosuppressed individuals), most recent (at the 
time of survey) vaccination coverage results by popu-
lation group for the 2010/11 influenza season (or most 
recent season if not available) and planned policy or 
operational changes across countries expected in 
forthcoming years. National survey returns were vali-
dated by the gatekeepers with authorities in their min-
istries of health. 
We present and compare vaccination coverage data 
for the older population, clinical risk groups, preg-
nant women and HCWs obtained from the three lat-
est consecutive VENICE surveys. All data provided in 
this paper for the 2009/10 influenza season refer to 
seasonal influenza vaccination during the 2009/10 
pandemic (coverage with the pandemic vaccines have 
already been reported by VENICE [17]). Influenza vac-
cination recommendations that are detailed by age 
group for the 2010/11 influenza season refer to vac-
cination regardless of other clinical risk indications. 
Vaccination coverage data in the countries covered by 
VENICE were provided for one, two or all three influ-
enza seasons, depending on data availability in each 
country. The methods used (administrative or survey) 
to calculate vaccination coverage for people in clinical 
risk groups and HCWs [18] are recorded in this paper. 
For comparison of vaccination coverage, we did not use 
any statistical test. 
Vaccination coverage data for the United Kingdom 
(UK) were provided separately for Northern Ireland, 
Wales, England and Scotland. In our analysis, the UK 
is counted as one country, but coverage data are pre-
sented for each part. Vaccination coverage for preg-
nant women in the UK was calculated separately for 




 Of the 29 EU/EEA countries participating in the VENICE 
project, 27 provided data for 2008/09 influenza season 
(Bulgaria and Luxembourg did not respond to the sur-
vey); 28 countries reported data for 2009/10 season 
(the UK did not respond to the survey, but provided 
vaccination coverage data); 28 countries responded to 
the survey that collected data for the 2010/11 influenza 
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season (Finland did not respond to the survey, but pro-
vided clarifying information regarding age groups rec-
ommended for vaccination for the 2010/11 season at 
the time of writing. Consequently, the number of coun-
tries in some parts of the results section in this paper 
was 29). 
Policy initiatives
At the time of completion of the 2010/11 influenza sea-
sonal survey (November 2011), it was reported that 
seven countries had updated a previous action plan 
and two had developed plans after the Council recom-
mendation to improve seasonal influenza vaccination 
coverage by 2014/15. The Netherlands had already 
achieved the target coverage. There was no report of 
any action plan for 18 countries. 
Vaccination recommendations
Age groups targeted for seasonal influenza vaccination
All 29 countries recommended seasonal influenza vac-
cination for the older-age population in 2010/11; how-
ever, the specified age differed between countries. Of 
the 29 countries, 20 recommended vaccination for indi-
viduals ≥65 years. In four countries (Germany, Greece, 
Iceland and the Netherlands), vaccination was recom-
mended for those aged ≥60 years. Two countries (Malta 
and Poland) recommended vaccination for individuals 
≥55 years; Slovakia recommended vaccination for indi-
viduals aged ≥59 years. The remaining two countries 
(Austria and Ireland) recommended vaccination for 
those ≥50 years. In Ireland, however, vaccination is 
only provided free of charge and vaccination coverage 
Table 1















–64 ≥50 ≥55 ≥59 ≥60 ≥65
Austria     X  X     
Belgium           X
Bulgaria           X
Cyprus           X
Czech Republic           X
Denmark           X
Estonia     X X     X
Finland  X         X
France           X
Germany          X  
Greece          X  
Hungary           X
Iceland          X  
Irelandb       X     
Italy           X
Latvia X          X
Lithuania           X
Luxembourg           X
Malta   X     X    
The Netherlands          X  
Norway           X
Poland     X   X    
Portugal           X
Romania           X
Slovakia    X     X   
Slovenia X          X
Spain           X
Sweden           X
United Kingdom           X
EEA: European Economic Area; EU: European Union. 
a All EU/EEA countries except Lichtenstein, surveyed by the Vaccine European New Integrated Collaboration Effort (VENICE) seasonal influenza 
survey, November 2011.
b Vaccination was recommended for individuals aged >50 years but only those aged >65 years were vaccinated free of charge. Vaccination 
coverage was calculated for those aged >65 years.
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monitored for individuals aged ≥65 years. Detailed 
information on age groups targeted for the 2010/11 
influenza season is presented in Table 1. 
Of the 29 responding countries, eight (Austria, Estonia, 
Finland, Latvia, Malta, Poland, Slovakia and Slovenia) 
reported recommending seasonal influenza vaccina-
tion for various age groups of healthy children aged <18 
years in the 2010/11 influenza season. In  Latvia and 
Slovenia, vaccination was recommended for children 
aged ≥6 months to 2 years; in Finland, vaccination was 
recommended for children aged ≥6 months to 3 years; 
in Malta, vaccination was recommended for children 
aged ≥6 months to 4 years; in Slovakia, vaccination 
was recommended for children aged <12 years. Austria, 
Estonia and Poland recommended vaccination for chil-
dren aged ≥6 months to <18 years. 
Table 2
Population groups recommended for seasonal influenza vaccination in EU/EEA countriesa during three influenza seasons
Recommendation for target population groups




b (n=28) 2010/11 (n=28)
Clinical risk groups, disorders
Chronic pulmonary diseases 27 28 28
Cardiovascular diseases 27 28 28
Renal diseases 25 28 28
Haematological/metabolic disorders 26 28 28
Immunosuppression due to disease or treatment 25 28 28
HIV/AIDS 24 24 25
Any condition compromising respiratory functionc 12 18 19
Hepatic diseases 15 17 19
Children on long-term aspirin therapy 18 17 16
Morbid obesity (body mass index >40 kg/m2) – – 9
Pregnancy-related recommendations
Vaccination recommended during pregnancy 10 16 22d 
     Any trimester – – 9
     Either 2nd or 3rd trimester – – 13
Postpartum if not vaccinated during pregnancy – – 1
Occupational setting
Healthcare workers 22 23 25
People in essential services (police and fire service) 5 8 8
Military personnel 6 9 10
Poultry industry workers 13 11 12
Families that raise poultry, pigs or waterfowl 4 9 9
Pig industry workers – – 8
Educational sector workers – – 5
Public transport workers – – 6
Energy sector workers – – 3
Finance/banking sector workers – – 4
Border control/Immigration/customs staff – – 4
Other settings/groups
Residents of long-term care facilities 22 24 25
Household contacts of: 
    Individuals belonging to the clinical risk groups – 10 14
    Children <6 months of age – 6 11
    Immunosupressed individuals – 9 16
    Older people (e.g. aged ≥65 years) – 4 10
AIDS: acquired immunodeficiency syndrome; EEA: European Economic Area; EU: European Union; HIV: human immunodeficiency virus.
Dashes in cells mean that this information was not previously collected, nor specifically asked. 
a  A total of 27 or 28 EU/EEA countries except Lichtenstein surveyed by the Vaccine European New Integrated Collaboration Effort (VENICE) 
seasonal influenza surveys.
b  The data refer to seasonal influenza vaccine recommendations in the 2009/10 pandemic influenza season. 
c  Any condition (e.g. cognitive dysfunction, spinal cord injuries, seizure disorders or other neuromuscular disorders) that can compromise 
respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.
d  Recommended for all pregnant women in 19 countries; for those with additional clinical risk in three countries.
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Only two countries reported changes in the age groups 
recommended for vaccination in the 2010/11 season 
compared with the 2009/10 season. Poland recom-
mended vaccination for those <18 years in 2010/11, 
which had not been recommended in previous sea-
sons. Hungary recommended vaccination for those 
aged ≥65 in 2010/11 instead of those aged ≥60 years 
as in 2009/10. 
Clinical risk groups targeted for seasonal influenza 
vaccination in the 2010/11 season
All 28 responding countries in 2010/11 recommended 
vaccination for individuals with chronic pulmonary, car-
diovascular and renal disease, those who were immu-
nosuppressed due to disease or treatment and those 
with haematological and metabolic disorders. A total of 
19 countries recommended vaccination for individuals 
with any condition compromising respiratory function. 
Nine countries recommended vaccination for individu-
als with morbid obesity (body mass index ≥40 kg/m2).
In comparison with previous VENICE surveys and since 
the Council recommendation, a number of countries 
had made changes to their seasonal influenza vaccina-
tion recommendations and policies compared with pre-
vious seasons, specifically related to risk groups. The 
number of countries that recommended vaccination for 
pregnant women increased (16 countries in 2009/10 vs 
22 countries in 2010/11). Of the 22 countries in 2010/11, 
19 recommended vaccination for all pregnant women; 
three recommended vaccination for pregnant women 
with an additional clinical risk condition. A total of 13 
countries recommended vaccination during the second 
or third trimester and nine countries recommended 
vaccination at any stage during pregnancy. 
From 2009/10 to 2010/11, more countries included a 
recommendation that household contacts of people 
in clinical risk groups, older individuals or children 
less than 6 months of age should be vaccinated (e.g. 
10 countries in 2009/10 vs 14 countries in 2010/11 for 
household contacts of individuals belonging to clinical 
risk groups; six countries in 2009/10 vs 11 countries in 
2010/11 for household contacts of children less than 
6 months of age) (Table 2). There were no substantial 
changes relating to recommendations regarding vacci-
nation of members of occupational groups. Of the 28 
responding countries, 20 recommended vaccination 
for all HCWs and five only to some HCWs in 2010/11 
(the recommendations differed in these five countries: 
e.g. staff with close contact with patients; or staff with 
no contact with patients, but contact with potentially 
contaminated material; or social care staff directly 
involved in frontline patient care). Three countries did 
not recommend vaccination for HCWs. 
Vaccination coverage rates
Overall, 23 countries provided vaccination cover-
age data. This is very similar to the situation before 
the Council recommendation (22 vs 23 countries for 
2008/09 and 2010/11, respectively). Six countries 
(Austria, Belgium, Bulgaria, Cyprus, Czech Republic 
and Greece) were unable to provide any group-spe-
cific coverage data in any of three influenza seasons 
surveyed.
Healthy children and adolescents 
Nine countries reported vaccination coverage data for 
a variety of age groups of children and adolescents 
calculated by administrative or survey methods for at 
least one of the three influenza seasons (Table 3). Six 
of these countries (Estonia, Finland, Latvia, Poland, 
Slovakia and Slovenia) recommended vaccination 
of children or adolescents, while three other coun-
tries (France, Italy and Portugal) provided vaccination 
Table 3
Vaccination coverage for seasonal influenza for children 





Vaccination coverage (%) by influenza season 
by age group
2008/09 2009/10b 2010/11 
Administrative method 
≥6 months–<2 years
Latvia 0.3 0.1 0.1
≥6 months–<3 years 
Finland – 32 –
≥6 months–<5 years
Estonia 1 1 –
Poland 2 1 1
Italy – 6.1 –
Slovenia 0.7 0.8 0.5
≥6 months–<10 years
France – – 13.8
≥6 months–14 years
Estonia – – 0.9
≥6 months–15 years
Slovakia 8.6 7.5 4.3
5–14 years
Estonia 2 1 –
Italy – 5.1 –
Poland 2.9 1.7 1.8
5–18 years
Slovenia 1.1 1.2 0.5
10–19 years
France – – 16.7
Survey method
≥6 months–4 years
France – 9.9 –
5–14 years
France – 6.5 –
≥6 months–15 years
Portugal – 13 9.6
EEA: European Economic Area; EU: European Union. 
Dashes in cells mean that vaccination coverage was not provided.
a Nine of all the EU/EEA countries except Lichtenstein surveyed 
by the Vaccine European New Integrated Collaboration Effort 
(VENICE) seasonal influenza survey.
b The data refer to seasonal influenza vaccine recommendations in 
the 2009/10 pandemic influenza season. 
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coverage for some age groups although vaccination 
was not recommended for healthy children and adoles-
cents in these countries. Two of the countries that rec-
ommended influenza vaccination for children did not 
provide vaccination coverage data (Austria and Malta). 
Older population groups
A total of 23 countries were able to provide vaccina-
tion coverage rates of their older population groups 
targeted for vaccination for two or three influenza sea-
sons (2008/09, 2009/10 or 2010/11), i.e. notwithstand-
ing the recommendations of the European Council and 
WHO, six countries were not gathering any age group-
specific data on vaccination coverage. The data pro-
vided for each country refer to the specific age group 
defined by each country as constituting the older pop-
ulation (≥50, ≥55, ≥59, ≥60 or ≥65 years). 
Vaccination coverage among older age groups ranged 
from 1% (Estonia) to 82% (the Netherlands) in 2008/09 
influenza season. The highest reported vaccination 
coverage rates were in the Netherlands and some parts 
of the UK (England, Northern Ireland and Scotland) that 
achieved or almost achieved EU 2014/15 target. Five 
countries (France, Germany, Ireland, Italy and Spain) 
reported vaccination coverage around 60% for this 
specific age group. Denmark, Finland, Luxembourg, 
Malta, Norway, Portugal  and Sweden reported vaccina-
tion coverage around 50%. In six  countries (Hungary, 
Iceland, Lithuania, Romania, Slovakia and Slovenia) 
vaccination coverage was below 50%. In the remaining 
three countries (Estonia, Latvia and Poland), vaccina-
tion coverage was about 10% or less. 
Comparing pre-pandemic, pandemic and post-pan-
demic influenza seasons, there were small decreases 
in vaccination coverage in half of the countries. In con-
trast, Ireland, Scotland and Wales reported coverage 
that was slightly higher in the post-pandemic influenza 
season in comparison with that during the pandemic 
(Figure 1). 
Clinical risk groups
Of 28 countries surveyed, seven were able to provide 
vaccination coverage rates for one, two or three influ-
enza seasons for people in clinical risk groups. The 
coverage varied, ranging from approximately 29% in 
Ireland (2009/10) to 70% in the Netherlands (2010/11) 
and 80% in Northern Ireland (2009/10). In all coun-
tries that reported vaccination coverage rates, except 
the Netherlands and Northern Ireland, vaccination 
coverage was well below the 2014/15 EU target. The 
Netherlands almost achieved and Northern Ireland had 
already achieved the target. 
Comparing pandemic and post-pandemic influenza 
seasons in some countries, there was a decrease in 
coverage of these risk groups (e.g. in Netherlands 
and Portugal); however, in others (e.g. Scotland), an 
increase in vaccination coverage was reported. 
Overall, three Member States (Romania, Slovenia and 
the UK) were able to report vaccination coverage rates 
among pregnant women. The coverage was low in 
Romania and Slovenia (3.7% and 2.4%, respectively). 
In the UK, there was variation in reported coverage, 
Figure 1
Reported seasonal influenza vaccination coverage in oldera population in 23 EU/EEA countriesb during three influenza 
seasons
EEA: European Economic Area; EU: European Union. 
a  Defined as those aged >55, >59, >60 or ≥65 years in the responding countries.
b All EU/EEA countries except Lichtenstein, surveyed by the Vaccine European New Integrated Collaboration Effort (VENICE) seasonal 
influenza survey. The United Kingdom is counted as one country here.
c  Reports for Sweden were received for only around 60% of the population for the 2009/10 influenza season.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































which was calculated separately for healthy pregnant 
women (37% and 65% in England and Scotland, respec-
tively) and for those with additional clinical risk factors 
(57% and 65% in England and Scotland, respectively) 
(Table 4).
Healthcare workers
A total of 10 of the countries were able to report vacci-
nation coverage for one, two or three influenza seasons 
for HCWs. The reported vaccination coverage varied, 
ranging from 12% (Norway and Wales in 2009/10) 
to 98% (Romania in 2008/09). In England, Hungary, 
Portugal and Scotland, coverage was between 30% 
and 50% in 2010/11. The remaining countries (France, 
Germany Norway, Slovenia, Spain and Wales), with 
exception of Romania, reported vaccination cover-
age ranged between 14% and 28% in 2010/11. When 
comparing the pandemic and post-pandemic influenza 
seasons, there was decrease in vaccination coverage 
in France, Germany, Hungary, Portugal and Spain, 
while increased vaccination coverage was reported in 
England, Wales and Norway. Detailed information is 
presented in Table 4.
Payment scheme for influenza vaccine
 Older individuals (aged ≥50, ≥55, ≥59, ≥60 or ≥65 years, 
depending on the recommendation in specific coun-
tries) received influenza vaccine free of charge in 14 
countries in 2010/11; seven of these countries reported 
vaccination coverage around 50% in older individuals. 
Of seven countries that recommended vaccination for 
children in the 2010/11 influenza season, only two 
offered the vaccine free of charge (Malta and Slovakia). 
In four of them (Austria, Estonia, Poland and Slovenia), 
the full cost was paid by the recipient and in Latvia, the 
vaccine was partly funded. 
The vaccine for members of clinical risk groups and 
HCWs was free of charge in 16 countries; for preg-
nant women and residents of long-stay care facilities, 
the vaccine was free of charge in 11 and 14 countries, 
respectively, in 2010/11 (Figure 2).
Figure 2
Payment scheme for influenza vaccine for different age, risk or target groups in EU/EEA countriesa in the 2010/11 influenza 
season
EEA: European Economic Area; EU: European Union; HCW: healthcare worker. 
a  EU/EEA countries except Lichtenstein, surveyed by the Vaccine European New Integrated Collaboration Effort (VENICE) seasonal influenza 
survey, November 2011.
b  Older population defined as those aged ≥55, ≥59, ≥60 or ≥65 years in the responding countries.
c  Occupations, clinical risk groups, pregnant women, HCWs and residents of long-stay care facilities as specified in Table 2, according to 
national recommendations. 
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Discussion
The analyses presented in this paper summarise infor-
mation obtained from annual surveys implemented by 
VENICE among EU/EEA Member States. The results pro-
vide part of the data used to monitor progress following 
the 2009 Council recommendation [8]. Other relevant 
data were collected by the European Commission for 
an interim report which was prepared in 2013 [19].  The 
same data can also be used to monitor WHO recom-
mendations for groups to be targeted for vaccination 
(revised in 2012)[20]. 
Interpretation of results for the period 2008/09 to 
2010/11 is complicated as there was both the intro-
duction of the seasonal influenza recommendation 
and the very varied experience of the pandemic and 
its vaccination campaigns across European countries 
[13,21,22]. Given the difficulties experienced with pan-
demic vaccination in some European countries, it is 
reassuring that coverage in the older age groups held 
up as well as it did in 2010/11. However, there has been 
little improvement in seasonal vaccination coverage 
in other risk groups despite national and the Council 
recommendations; in some countries, coverage has 
decreased. Since only nine countries in November 2011 
reported having action plans to implement the Council 
recommendation, it may be that countries delayed 
implementing the recommendation, given their pan-
demic experience. 
The challenges that countries face implementing 
national and Council recommendation varied and may 
be related to different knowledge, attitudes and prac-
tices, risk perception, health systems and related cost 
issues that differ by country across the region. In addi-
tion, media coverage and public debate about vaccine 
effectiveness, which depends on the match with circu-
lating vaccine strains, can negatively impact vaccina-
tion coverage [23,24]. The experience of narcolepsy 
following use of pandemic vaccines in some EU/EEA 
countries undoubtedly had a negative impact on public 
perception of vaccine safety, which may also have led 
to subsequent decrease in coverage in some countries 
[25,26]. Anti-vaccination groups and media coverage 
may also have contributed to this decrease [27].
Many countries appear to have had difficulties moni-
toring coverage in target groups other than older peo-
ple. This may be related to differences in health system 
delivery, how vaccination is implemented in the coun-
try and data collection or information systems avail-
able for capturing such data. What is possible in one 
country may not be easily adopted in another. 
During and after the pandemic, a number of countries 
made changes to national recommendations regard-
ing additional risk groups who would benefit from 
vaccination, influenced by collected epidemiological 
data during pandemic. More countries recommended 
vaccination of pregnant women and individuals with 
morbid obesity. Morbid obesity was recognised as an 
independent risk factor for hospitalisation and death 
due to pandemic influenza [28-30]. Before the pan-
demic, no EU/EEA country had included this group in 
recommendations for influenza vaccination.
There is currently no consensus within European coun-
tries regarding routine seasonal influenza vaccination 
of children, although such recommendation is now 
standard in the United States [31] and WHO is recom-
mending vaccination of children ≥6 to 59 months of age 
[20]. Since the pandemic, more countries are adopting 
such recommendations [32]. The reluctance of coun-
tries to recommend routine seasonal influenza vaccina-
tion of children may reflect a lack of evidence regarding 
cost-effectiveness and risk perception of this measure 
[32]. Partially, this reflects that there are so few data 
from Europe. Even in those countries that have recom-
mended seasonal vaccination of children for a number 
of years, the reasons for low coverage have not been 
explored in our study but it may reflect low risk percep-
tion among the public and the medical community. Live 
intranasal vaccines that do not require injection were 
licensed by the European Medicines Agency in 2010 
and may increase acceptance and delivery of annual 
vaccination among those EU/EEA countries recom-
mending vaccination for children [33].
The 2010/11 survey found an increase in the number of 
countries recommending seasonal influenza vaccina-
tion for pregnant women. This increase may reflect bet-
ter awareness of influenza morbidity among pregnant 
women that was notably evident during the pandemic 
[34-36]. A body of literature has demonstrated the 
safety and effectiveness of vaccine in this group and 
there may also be benefits for the fetus and newborn 
child [37,38]. It is disappointing that only three of the 
22 countries recommending vaccination of pregnant 
women were able to report coverage data for this high-
risk population. In line with a growing consensus on 
the importance of vaccination for pregnant women, it is 
clear that this is an area in which countries should seek 
to improve information on programme implementation. 
In operational terms, HCWs are a crucial group involved 
in influenza vaccination. They should be vaccinated to 
protect their patients; they have to give the vaccine and 
to advocate the vaccination to their patients. Repeated 
surveys have indicated that it is the opinion of the 
doctor or nurse that is most important in determining 
whether or not a person is immunised [39-41]. While 
most countries have long-standing recommendations 
to immunise HCWs with seasonal influenza vaccine, 
only a third could report vaccination coverage rates 
for any season. In addition, in most of these countries, 
coverage among HCWs is still low (with Romania and 
Hungary being the exceptions) and does not show 
signs of improvement. Moreover, it is surprising that 
coverage data for staff working in long-term care facili-
ties were provided by only one country and coverage 
data for residents of such facilities was known in only 
two countries.
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Costs associated with vaccine can be a deterrent or 
barrier for vaccination, particularly if the costs are 
borne by the individual [27]. We found that half of the 
countries surveyed have adopted a policy of provision 
of vaccine free of charge, in total or in part, predomi-
nantly for elderly people, individuals with chronic dis-
ease, pregnant women and HCWs. However, four of 
seven countries reported that the full cost is paid for 
vaccination of children. 
Survey limitations
The survey data presented here have limitations. 
Comparison of vaccination coverage data is difficult 
across European countries as different methods of 
estimating coverage are often used; within a given 
country, comparisons between years may be difficult if 
methods or response rate differ by year. How countries 
enumerate the denominator data (numbers eligible 
for vaccination) is often difficult to determine, espe-
cially when it comes to less specific groups, such as 
the clinical risk groups and HCWs. The enumeration of 
numbers vaccinated (numerator data) also has limita-
tions as countries may use either data provided from 
administrative records or immunisation registries or 
from others surveys, both of which may have their own 
limitations. While the surveys report exact details on 
how numerator and denominator data are calculated, 
the surveys do not explore or report the specific limita-
tions. Denominator data for clinical risk groups are par-
ticularly difficult to estimate accurately for most EU/
EEA countries, reflecting the lack of information sys-
tems (disease registers) or other standardised method-
ologies for collecting these data in the countries. Some 
countries have used population surveys to estimate the 
number of individuals at risk. But even this may not be 
comparable between countries as a variety of method-
ologies have been used (e.g. household surveys, mail, 
face to face, telephone interviews). The reasons for low 
or high uptake across EU/EEA countries were not col-
lected in these surveys: future studies are needed.
Recommendations
Additional efforts are needed to increase vaccination 
coverage among older population groups, individuals 
with a clinical risk indication, pregnant women and 
HCWs in order to achieve the target of 75% by the win-
ter of 2014/15. The continued low vaccination coverage 
levels reported for HCWs are of concern and highlight 
the need for more focused and intensive health promo-
tion and implementation of vaccination campaigns. 
Some countries have achieved coverage higher than 
the target and there is value in sharing information 
between countries on how this has been achieved. 
Additional country-level research is required to identify 
the reasons for non-vaccination so that specific issues 
can be addressed through more targeted promotion 
campaigns. All countries should strive to collect infor-
mation on vaccination coverage for older age groups as 
well as those in other risk groups, without which moni-
toring progress is not possible. 
VENICE gatekeepers
Austria: Christina Kral, Jean Paul Klein; Belgium: Pierre 
Van Damme, Martine Sabbe, Françoise Wuillaume; 
Bulgaria: Mira Kojouharova; Czech Republic: Bohumir 
Kriz, Jan Kyncl; Cyprus: Chrystalla Hadjianastassiou, 
Soteroulla Soteriou; Denmark: Palle Valentiner-Branth, 
Tyra Grove Krause, Hanne-Dorte Emborg; England: 
Richard Pebody; Estonia: Natalia Kerbo, Irina Filippova; 
Finland: Tuija Leino; France: Daniel Levy-Bruhl, Isabelle 
Bonmarin; Germany: Sabine Reiter, Ole Wichmann; 
Greece: Theodora Stavrou; Hungary:-Zsuzsanna 
Molnàr; Iceland: Thorolfur Gudnason; Ireland: Suzanne 
Cotter; Italy: Fortunato D’Ancona, Caterina Rizzo; 
Latvia: Jurijs Perevoscikovs; Lithuania: Egle Savickiene; 
Luxembourg: Berthet Francoise; Malta-Tanya Melillo; 
the Netherlands: Bianca Snijders, Hester de Melker; 
Northern Ireland: Brian Smyth; Norway: Berit Feiring; 
Poland: Iwona Stankiewicz; Portugal: Paula Valente, 
Teresa Fernandes; Romania: Rodica Popescu; Scotland: 
Jim McMenamin ; Slovakia: Helena Hudecova; Slovenia: 
Alenka Kraigher, Veronika Učakar; Spain: Aurora Limia, 
Isabel Pachon del Amo; Sweden: Annika Linde; Wales: 
Simon Cottrell.
The gatekeepers are also listed in the 2010/11 report 
on the VENICE website [17].
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